The company expired its plan on July 20, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.41 CNY | -2.00% | -8.02% | +0.62% |
09/05 | Pacific Shuanglin Bio-pharmacy Subsidiary Gets Plasmapheresis License | MT |
26/04 | Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+0.62% | 283.04Cr | |
+0.10% | 9.14TCr | |
+3.16% | 4.11TCr | |
-11.10% | 3.43TCr | |
+53.99% | 2.53TCr | |
-9.41% | 1.28TCr | |
-12.25% | 1.16TCr | |
-44.00% | 1.14TCr | |
+5.77% | 915.59Cr | |
-6.90% | 821.79Cr |
- Stock Market
- Equities
- 000403 Stock
- News Pacific Shuanglin Bio-pharmacy Co., LTD
- Pacific Shuanglin Bio-pharmacy Co., LTD's Equity Buyback announced on September 1, 2022 has expired with 1,968,378 shares, representing 0.27% for CNY 40.1 million.